vs
Side-by-side financial comparison of COGENT COMMUNICATIONS HOLDINGS, INC. (CCOI) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $240.5M, roughly 1.3× COGENT COMMUNICATIONS HOLDINGS, INC.). Bio-Techne runs the higher net margin — 16.4% vs -12.8%, a 29.2% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-1.5% vs -4.7%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs -4.9%).
Cogent Communications Holdings, Inc. is a multinational internet service provider based in the United States. Cogent's primary services consist of Internet access and data transport, offered on a fiber optic, IP data-only network, along with colocation in data centers.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CCOI vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $240.5M | $311.4M |
| Net Profit | $-30.8M | $51.0M |
| Gross Margin | 46.6% | 66.9% |
| Operating Margin | -4.7% | 24.2% |
| Net Margin | -12.8% | 16.4% |
| Revenue YoY | -4.7% | -1.5% |
| Net Profit YoY | 28.9% | 126.0% |
| EPS (diluted) | $-0.63 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $240.5M | $295.9M | ||
| Q3 25 | $241.9M | — | ||
| Q2 25 | $246.2M | $317.0M | ||
| Q1 25 | $247.0M | $316.2M | ||
| Q4 24 | $252.3M | $297.0M | ||
| Q3 24 | $257.2M | $289.5M | ||
| Q2 24 | $260.4M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $-30.8M | $38.0M | ||
| Q3 25 | $-41.5M | — | ||
| Q2 25 | $-57.8M | $-17.7M | ||
| Q1 25 | $-52.0M | $22.6M | ||
| Q4 24 | $-43.3M | $34.9M | ||
| Q3 24 | $-63.1M | $33.6M | ||
| Q2 24 | $-32.3M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | 46.6% | 64.6% | ||
| Q3 25 | 45.6% | — | ||
| Q2 25 | 44.2% | 62.7% | ||
| Q1 25 | 44.4% | 67.9% | ||
| Q4 24 | 38.5% | 65.3% | ||
| Q3 24 | 37.2% | 63.2% | ||
| Q2 24 | 40.0% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | -4.7% | 18.4% | ||
| Q3 25 | -7.5% | — | ||
| Q2 25 | -12.8% | -7.5% | ||
| Q1 25 | -16.3% | 12.2% | ||
| Q4 24 | -13.2% | 16.0% | ||
| Q3 24 | -22.5% | 13.8% | ||
| Q2 24 | -18.1% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | -12.8% | 12.8% | ||
| Q3 25 | -17.2% | — | ||
| Q2 25 | -23.5% | -5.6% | ||
| Q1 25 | -21.1% | 7.1% | ||
| Q4 24 | -17.2% | 11.7% | ||
| Q3 24 | -24.5% | 11.6% | ||
| Q2 24 | -12.4% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $-0.63 | $0.24 | ||
| Q3 25 | $-0.87 | — | ||
| Q2 25 | $-1.21 | $-0.11 | ||
| Q1 25 | $-1.09 | $0.14 | ||
| Q4 24 | $-0.89 | $0.22 | ||
| Q3 24 | $-1.33 | $0.21 | ||
| Q2 24 | $-0.68 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $148.5M | $209.8M |
| Total DebtLower is stronger | $1.7B | — |
| Stockholders' EquityBook value | $-63.8M | $2.1B |
| Total Assets | $3.1B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $148.5M | $172.9M | ||
| Q3 25 | $147.1M | — | ||
| Q2 25 | $213.7M | $162.2M | ||
| Q1 25 | $153.8M | $140.7M | ||
| Q4 24 | $198.5M | $177.5M | ||
| Q3 24 | $279.2M | $187.5M | ||
| Q2 24 | $384.4M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.7B | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | $1.5B | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $-63.8M | $2.0B | ||
| Q3 25 | $-39.2M | — | ||
| Q2 25 | $46.7M | $1.9B | ||
| Q1 25 | $142.8M | $2.0B | ||
| Q4 24 | $222.8M | $2.1B | ||
| Q3 24 | $323.6M | $2.1B | ||
| Q2 24 | $415.5M | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $3.1B | $2.5B | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $3.3B | $2.6B | ||
| Q1 25 | $3.1B | $2.6B | ||
| Q4 24 | $3.2B | $2.7B | ||
| Q3 24 | $3.2B | $2.7B | ||
| Q2 24 | $3.3B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | 6.53× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | — |
| Free Cash FlowOCF − Capex | $-43.0M | — |
| FCF MarginFCF / Revenue | -17.9% | — |
| Capex IntensityCapex / Revenue | 15.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-198.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-6.0M | — | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $-44.0M | $98.2M | ||
| Q1 25 | $36.4M | $41.1M | ||
| Q4 24 | $14.5M | $84.3M | ||
| Q3 24 | $-20.2M | $63.9M | ||
| Q2 24 | $-22.2M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-43.0M | — | ||
| Q3 25 | $-33.1M | — | ||
| Q2 25 | $-100.2M | $93.3M | ||
| Q1 25 | $-21.7M | $31.0M | ||
| Q4 24 | $-31.6M | $77.5M | ||
| Q3 24 | $-79.5M | $54.7M | ||
| Q2 24 | $-70.9M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | -17.9% | — | ||
| Q3 25 | -13.7% | — | ||
| Q2 25 | -40.7% | 29.4% | ||
| Q1 25 | -8.8% | 9.8% | ||
| Q4 24 | -12.5% | 26.1% | ||
| Q3 24 | -30.9% | 18.9% | ||
| Q2 24 | -27.2% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 15.4% | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | 22.8% | 1.5% | ||
| Q1 25 | 23.5% | 3.2% | ||
| Q4 24 | 18.3% | 2.3% | ||
| Q3 24 | 23.0% | 3.2% | ||
| Q2 24 | 18.7% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCOI
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
